Albendazole

In a case report from 2012, a 25-year-old woman developed telogen effluvium, a form of temporary hair loss, after being treated with albendazole for cutaneous larva migrans. She had taken two courses of oral albendazole at a dosage of 400 mg/day for one week each over the two months before presenting with hair loss. The diagnosis of albendazole-induced telogen effluvium was made after other causes of alopecia were ruled out, as evidenced by the presence of telogen club hairs during a pull test. The patient's hair loss was not treated, but she was scheduled for monthly follow-ups, and her hair returned to normal by the last follow-up. The authors concluded that albendazole was the likely cause of the hair loss.